Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TUBB1 | Q9H4B7 | 8/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.49 |
| ▸ | TUBB | P07437 | 4/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.49 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.49 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.49 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.49 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.49 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.49 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.49 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.49 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.49 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL139963 | 0.82 | MAOB (0.61) | ALDH1A1CYP1A2MAPTTSHRCYP3A4 | |
| SCHEMBL27090 | 0.78 | CA2 (0.54) | ALDH1A1CYP1A2TUBB1TUBB4ATUBB | |
| SCHEMBL2811538 | 0.76 | CA2 (0.41) | ALDH1A1CYP1A2MAPTTSHRCYP3A4 | |
| SCHEMBL68212 | 0.76 | MAOB (0.67) | ALDH1A1AOX1CYP1A2MAPTTUBB1 | |
| SCHEMBL29692356 | 0.76 | MAOB (0.67) | ALDH1A1AOX1CYP1A2MAPTTUBB1 | |
| SCHEMBL581508 | 0.74 | TUBB4A (0.63) | ALDH1A1AOX1CYP1A2MAPTTUBB1 | |
| SCHEMBL352907 | 0.74 | MAPT (0.47) | ALDH1A1MAPTTSHRCYP3A4ALOX15 | |
| SCHEMBL561678 | 0.74 | PTGS2 (0.50) | ALDH1A1CYP1A2MAPTTUBB1CYP3A4 | |
| SCHEMBL29398758 | 0.74 | ACHE (0.62) | ALDH1A1AOX1CYP1A2MAPTTUBB1 | |
| SCHEMBL218637 | 0.74 | ACHE (0.62) | ALDH1A1AOX1CYP1A2MAPTTUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112707899-B | Preparation method of quininol | 东莞市东阳光动物保健药品有限公司 | 2023-10-17 | — | — | CN | claimed |
| CN-116640106-A | Phenylpiperazine compound and preparation method and application thereof | 郑州大学 | 2023-08-25 | — | — | CN | claimed |
| EP-4178959-A1 | NITROGEN HETEROCYCLIC CYTOKININ DERIVATIVES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND USE THEREOF | Univerzita Palackého v Olomouci (CZ) | 2023-05-17 | — | — | EP | claimed |
| WO-2023078482-A1 | HETEROCYCLIC PURINE CYTOKININ DERIVATIVES, THEIR USE IN WOUND HEALING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2023-05-11 | — | — | WO | claimed |
| US-11643413-B2 | 9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2023-05-09 | — | — | US | claimed |
| EP-3615535-B1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | UNIV PALACKEHO (CZ) | 2022-06-15 | — | — | EP | claimed |
| WO-2022012702-A1 | NITROGEN HETEROCYCLIC CYTOKININ DERIVATIVES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2022-01-20 | — | — | WO | claimed |
| CN-112707899-A | Preparation method of quininol | 东莞市东阳光动物保健药品有限公司 | 2021-04-27 | — | — | CN | claimed |
| US-20200157105-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-05-21 | — | — | US | claimed |
| EP-3615535-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | Univerzita Palackého v Olomouci (CZ) | 2020-03-04 | — | — | EP | claimed |
| EP-1682544-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-07-26 | — | — | EP | claimed |
| WO-2006072792-A2 | COMPOUNDS WHICH BIND TO THE ACTIVE SITE OF PROTEIN KINASE ENZYMES | GALAPAGOS NV (BE) | 2006-07-13 | — | — | WO | claimed |
| EP-1644365-A2 | PYRAZINE AND PYRIDINE DERIVATIVES AS RHO KINASE INHIBITORS | Biofocus Discovery Ltd (GB) | 2006-04-12 | — | — | EP | claimed |
| US-20050187240-A1 | Aaptamine and isoaaptamine and structural modifications thereof | THE ARIZONA BOARD OF REGENTS, ACTING FOR AND ON BEHALF OF THE ARIZONA STATE UNIVERSITY | 2005-08-25 | — | — | US | claimed |
| WO-2005048945-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-02 | — | — | WO | claimed |
| WO-2005003101-A2 | PYRAZINE AND PYRIDINE DERIVATIVES AS RHO KINASE INHIBITORS | BIOFOCUS DISCOVERY LIMITED (GB) | 2005-01-13 | — | — | WO | claimed |
| EP-0941998-B1 | 3,6-ketal macrolide antibiotics | PFIZER PROD INC (US) | 2004-09-01 | — | — | EP | claimed |
| US-6043226-A | TREATING BACTERIAL, PARASITIC AND PROTOZOAL INFECTIONS | PFIZER INC. (US) | 2000-03-28 | — | — | US | claimed |
| CN-1244532-A | 3,6-aldehyde acetal and enol ether large ring lactone vitamine | PFIZER PRODUCTS CO (US) | 2000-02-16 | — | — | CN | claimed |
| EP-0941998-A2 | 3,6-ketal and enol ether macrolide antibiotics | Pfizer Products Inc. (US) | 1999-09-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187240-A1 | Aaptamine and isoaaptamine and structural modifications thereof | HNMT, INMT, PNMT | ALDH1A1 878/4885AOX1 2232/4885CYP1A2 2870/4885 |
| US-20200157105-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | ADORA2A, UNG, P2RY6 | ALDH1A1 469/4885AOX1 115/4885CYP1A2 1744/4885 |
| US-11643413-B2 | 9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders | ADORA2A, UNG, P2RY6 | ALDH1A1 469/4885AOX1 115/4885CYP1A2 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.